Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
17 Jun 2024
17 Jun 2024
Historique:
revised:
10
05
2024
received:
29
02
2024
accepted:
29
05
2024
medline:
17
6
2024
pubmed:
17
6
2024
entrez:
17
6
2024
Statut:
aheadofprint
Résumé
Crovalimab is a novel C5 complement inhibitor that enables rapid and sustained C5 inhibition with subcutaneous, low-volume self-administration every 4 weeks. COMMODORE 2 (NCT04434092) is a global, randomized, open-label, multicenter, phase 3 trial evaluating the non-inferiority of crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria not previously treated with C5 inhibition. C5 inhibitor-naive patients with lactate dehydrogenase (LDH) ≥2 × upper limit of normal (ULN) were randomized 2:1 to crovalimab or eculizumab. Co-primary efficacy endpoints were proportion of patients with hemolysis control (centrally assessed LDH ≤1.5 × ULN) and proportion with transfusion avoidance. Secondary efficacy endpoints were proportions of patients with breakthrough hemolysis, stabilized hemoglobin, and change in FACIT-Fatigue score. The primary treatment period was 24 weeks. Two hundred and four patients were randomized (135 crovalimab; 69 eculizumab). Crovalimab was non-inferior to eculizumab in the co-primary endpoints of hemolysis control (79.3% vs. 79.0%; odds ratio, 1.0 [95% CI, 0.6, 1.8]) and transfusion avoidance (65.7% vs. 68.1%; weighted difference, -2.8 [-15.7, 11.1]), and in the secondary efficacy endpoints of breakthrough hemolysis (10.4% vs. 14.5%; weighted difference, -3.9 [-14.8, 5.3]) and hemoglobin stabilization (63.4% vs. 60.9%; weighted difference, 2.2 [-11.4, 16.3]). A clinically meaningful improvement in FACIT-Fatigue score occurred in both arms. Complete terminal complement activity inhibition was generally maintained with crovalimab. The safety profiles of crovalimab and eculizumab were similar with no meningococcal infections. Most patients who switched from eculizumab to crovalimab after the primary treatment period preferred crovalimab. These data demonstrate the positive benefit-risk profile of crovalimab.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.
Références
Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253‐1258.
Socié G, Mary JY, deGramont A, et al. Paroxysmal nocturnal haemoglobinuria: long‐term follow‐up and prognostic factors. Lancet. 1996;348(9027):573‐577.
Risitano AM, Marotta S, Ricci P, et al. Anti‐complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157.
Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233‐1243.
Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5‐inhibitor‐experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540‐549.
Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530‐539.
Kelly RJ, Hill A, Arnold LM, et al. Long‐term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786‐6792.
Groth M, Singer S, Niedeggen C, et al. Development of a disease‐specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ‐AA/PNH)‐report on phases I and II. Ann Hematol. 2017;96(2):171‐181.
Kaiser K, Yount SE, Martens CE, et al. Assessing preferences for rare disease treatment: qualitative development of the paroxysmal nocturnal hemoglobinuria patient preference questionnaire (PNH‐PPQ©). Patient Prefer Adherence. 2020;14:705‐715.
Fukuzawa T, Sampei Z, Haraya K, et al. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement‐mediated diseases. Sci Rep. 2017;7(1):1080.
Röth A, Nishimura JI, Nagy Z, et al. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020;135(12):912‐920.
Buatois SBK, Henrich A, Jaminion F, Zhang Y, Sostelly A. Pharmacokinetic characterization and exposure‐response relationship of crovalimab in the COMPOSER and COMMODORE 3 trials of patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2022;140(Suppl 1):2918‐2920.
Röth A, Ichikawa S, Ito Y, et al. Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: long‐term results from the phase I/II COMPOSER trial. Eur J Haematol. 2023;111(2):300‐310.
Liu H, Xia L, Weng J, et al. Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor‐naive patients with PNH (COMMODORE 3): a multicenter, phase 3, single‐arm study. Am J Hematol. 2023;98(9):1407‐1414.
Scheinberg P, Clé DV, Kim JS, et al. Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement‐inhibitor experienced patients with PNH. Am J Hematol. 2024. doi:10.1002/ajh.27413
Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528‐538.
Cella D, Johansson P, Ueda Y, et al. Clinically important difference for the FACIT‐fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data. J Patient Rep Outcomes. 2023;7(1):63.
Butt Z, Rao AV, Lai JS, Abernethy AP, Rosenbloom SK, Cella D. Age‐associated differences in fatigue among patients with cancer. J Pain Symptom Manag. 2010;40(2):217‐223.
Montan I, Löwe B, Cella D, Mehnert A, Hinz A. General population norms for the functional assessment of chronic illness therapy (FACIT)‐fatigue scale. Value Health. 2018;21(11):1313‐1321.
Sostelly A, Buatois S, Soubret A, et al. Exposure‐response relationship of the SMART‐Ig anti‐hC5 antibody crovalimab (SKY59): results from the umbrella phase 1/2 composer trial in healthy volunteers and PNH patients. Blood. 2019;134(Suppl 1):3745.
Schrezenmeier H, Muus P, Socié G, et al. Baseline characteristics and disease burden in patients in the international paroxysmal nocturnal hemoglobinuria registry. Haematologica. 2014;99(5):922‐929.
Schrezenmeier H, Röth A, Araten DJ, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the international PNH registry. Ann Hematol. 2020;99(7):1505‐1514.
Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840‐1847.